Natural killer (NK) cells can be defined on the basis of their ability to lyse certain tumour cells in a manner which is not dependent upon the expression of MHC molecules. In man, such 'natural' cytotoxicity is displayed mainly by CD3/ CD16+ cells with the morphology of large granular lymphocytes (LGL) (Timonene et al., 1981; Ortaldo et al., 1986; Lanier et al., 1986) . NK cells can also be stimulated by IL-2 or IFN-y to express a broader range of cytotoxicity, known as lymphokine activated killer (LAK) activity. Their ability to lyse tumour cells in vitro has led to the experimental use of NK and LAK cells in the immunotherapy of some types of human cancer. This has occasionally led to tumour regression and/or improved clinical prognosis in advanced renal cell cancers and melanomas (Lotze et al., 1986; Mule et al., 1986) .
However, there is also evidence to suggest that the cytotoxicity of NK cells towards tumour cells may actually be markedly reduced once they infiltrate the microenvironment of a malignant tumour (Moy et al., 1985; Lotzova, 1988; Nakamura et al., 1988) . Indeed, malignant tissues release factors which suppress various immune functions in draining lymph nodes (Wen et al., 1989) , and cultured tumour cells have been shown to inhibit the generation of LAK cells in vitro (Guillou et al., 1989) . That factors produced by the malignant cell population itself may mediate, at least in part, this immunosuppression is given credance by the finding that factors known to be produced by human cancer cells, such as TGF-I or prostaglandin E2, markedly inhibit the cytotoxicity of NK and LAK cells in vitro (Rook et al., 1986; Wahl et al., 1988; Leung, 1989; Luger et al., 1989) .
NK cells secrete a range of cytokines, including IFN-y, IL-2, (Djeu et al., 1982) and TNF-a (Peters et al., 1986) which are capable of directly lysing neoplastic cells in a time dependent manner (Uchida et al., 1985; Ruggerio et al., 1987) . Recently, interleukins 4 and 6, which are also NK cell products (Tamm et al., 1989) have been shown to alter the proliferation and metastatic potential of malignant cells in vitro (Pusztai et al., 1991) . Taken together, these findings suggest that NK cells may contribute a number of cytokines to the complex cytokine network which exists within the microenvironment of solid human tumours (Lewis, 1991) , and which collectively regulates the activity of both resident neoplastic cells and immune cells infiltrating such tissues.
A sensitive immunoassay called the reverse haemolytic plaque assay (RHPA) has recently been introduced for the measurement of cytokine secretion by individual, immunoidentified human cells (Lewis et al., 1990) . In the present report, the RHPA has been used to investigate the influence of the tumour microenvironment on the release of IFN--and IL-4 by individual human CD16+ NK cells. To do this, the secretory activity of NK cells derived from both tumour and the peripheral blood samples of patients with ductal invasive breast carcinoma were compared. In addition, experiments were undertaken to investigate the effects of soluble mediators released by the breast adenocarcinoma cell lines, MCF-7 and MDA-231 PN9, on the secretion of cytokines by NK cells in vitro.
Materials and methods
Isolation of mononuclear cells from the peripheral blood of cancer patients Peripheral blood samples (10 ml) were obtained from patients undergoing mastectomy (prior to surgery). Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Hypaque density gradients. Briefly, this involved diluting whole blood samples 1: 1 (v/v) in calcium and magnesium-free Hank's buffered salt solution (HBSS). The resultant cell suspensions were then washed three times before being carefully layered onto Ficoll-Hypaque cushions. After centrifugation for 25 min at 450 g, cells in the lymphocyte layer were collected and washed by centrifugation/resuspension three times in HBSS. This procedure routinely yielded 1-5 x 106 cells ml-'.
Enrichment of NK cells from the peripheral blood of healthy donors Human NK cells were isolated from 1,000 ml buffy coat preparations from five healthy female donors. PBMC were isolated using Ficoll-Hypaque density gradients as outlined above. The resulting cell pellet was resuspended in complete culture medium (see below) and incubated in large plastic culture dishes for 60 min at 37C to remove plastic-adherent monocytes. Non-adherent cells were harvested and then incubated in nylon wool columns for 30 min at 37°C to remove B cells (Julius et al., 1973) . T cells were removed by the negative panning technique (Garcia-Penarrubia & Bankhurst, 1989 Culture conditions and preparation of tumour cell supernatants Cultures of MCF-7 or MDA-231-PN-9 cells were maintained in RPMI 1640 medium supplemented with 2 mm of glutamine, 10% foetal calf serum, 1OOIU ml-' penicillin G and 100 ug ml1' streptomycin (complete culture medium) at 37'C in air/5% CO2. All culture reagents used were obtained from Gibco, Paisley, UK. The human breast cancer cell lines, MCF-7 and MDA-231 PN-9, were propagated in complete culture to medium to near (>90%) confluence. Cells were incubated with fresh medium for 24 h and the medium then removed and centrifuged at 5,000 g for 20 min. The supernatant was filtered (pore size 0.2 jAm) and used immediately as conditioned medium in subsequent medium-transfer experiments. Small aliquots of each batch of conditioned medium were transferred to glass slides and stained with haemotoxylin/ eosin to check for the absence of any contaminating tumour cells.
Reverse haemolytic plaque assay The secretion of IFN-y and IL-4 was measured using the RHPA as previously described for cytokines (Lewis et al., 1990) . Mononuclear human cells were suspended in RPMI 1640 medium supplemented with 0.1% bovine serum albumin, 2 mM glutamine and antibiotics (assay medium) and then mixed with ovine red blood cells (Serotec, Kidlington, UK) to which staphylococcal protein A (Sigma Chemicals, Dorset, UK) had been coupled using the chromium chloride method. This cell suspension was allowed to settle in Cunningham chambers for 45 min at 37°C in air/5% CO2. Nonattached cells were removed with prewarmed assay medium and the chambers filled with a 1:50 dilution of polyclonal rabbit antisera to either native human IFN-' or recombinant human IL-4 (Genzyme, USA). After incubation for 6 h, plaque formation was induced by infusion into the chambers of a 1:50 dilution of guinea pig complement in assay medium. The cell monolayers were then fixed with 2% glutaraldehyde (v/v) 
Results
Immunocytochemical labelling of cell preparations used in the RHPA Table I indicates the higher proportions of cells expressing T (CD3, CD4 and CD8) and NK cell (CD 16) antigens in PBMC isolated from breast cancer patients (after Ficollhypaque purification) than in cell preparations directly isolated from enzymatically-dispersed breast tumours. However, a slightly higher frequency of CD16+ cells were seen in dispersed tumour-associated mononuclear cells.
Negative panning of PBMC from healthy donors reproducibly enriched the proportion of CD16+ cells to >65%, and depleted cells bearing the CD3, CD4 and CD8 antigens to <5% (data not shown). Fifteen to twenty per cent of CD16+ NK cells from healthy donors enriched in this way secreted IFN-'y, whereas fewer than 2% of CD3+ or CD4+ cells secreted this cytokine in the RHPA (Table II) . By (Table II) . A higher proportion of CD4+ cells isolated from breast tumours (i.e. 20%) was found to release IFN-y than those isolated from the peripheral blood (i.e. 3%) of the same patients (Table II) .
To determine the identity of the main producer cell type(s) for IFN-y and IL-4 in the various cell preparations used in these studies, the proportion of the total plaque-forming cells bearing each of the CD antigens was calculated. The majority (i.e. 80-90%) of cells secreting these cytokines in the RHPA were seen to be CD3 or CD16+, irrespective of whether they were derived from healthy donors or patients with breast malignancies (data not shown).
Comparison of the secretory activity of NK cells derivedfrom the peripheral blood or tumours of breast cancer patients Figure 1 illustrates the appearance of a haemolytic plaque formed by an NK cell secreting IFN-y. The secretory cell is surrounded by an area of erythrocyte ghosts (plaque). Tumour-associated NK cells released significantly (P <0.01) more IFN-y and IL-4 than those from the peripheral blood of the same patients (Figure 2 ). This difference was not due to the collagenase treatment of tumour-associated NK cells, as incubation of peripheral blood NK cells with collagenase for 2 h did not result in alterations in cytokine release (data not shown).
It should be noted that IFN-' secretion was consistently detected in every blood and biopsy sample. By contrast, the release of IL-4 was only detected in blood samples from 50% Effect of medium conditioned by breast cancer lines on the secretory activity of NK cells For these experiments, NK cell enriched populations of PBMC were used (see above). Figure 3 illustrates (Kelly et al., 1988) .
In the present report we have employed a technique which permits the detection of cytokine secretion at the single cell level to investigate the cytokine communication which occurs in malignant tissues between resident malignant cells and NK cells. Since the area of haemolysis surrounding a secreting cell in the RHPA has been shown to be directly proportional to the amount of product secreted (Neill et al., 1987) , this technique allows the quantitation of cytokine secretion by individual cells and its modulation by various stimuli. The coupling of the RHPA with immunocytochemistry to phenotype producer cells allows the contributions made by various cell types to the overall level of secretion of a given cytokine to be assessed.
Cytokine levels in the serum can vary between individuals, but are usually a stable individual property (Moelvig et al., 1988) . For this reason, we chose to compare the cytokinesecreting activity of tumour-infiltrating NK cells with those from the blood of the same patients. Our studies indicate that CD16+ NK cells are the main source of IFN-y spontaneously secreted in short-term cultures of human PBMC or dispersed malignant breast tumours. This correlates well with the finding that it is NK cells, rather than T cells, which are the major producer cells for IFN-'y in vitro in the absence of exogenous stimulation (Young & Ortaldo, 1987) .
That NK cells secrete IL-4, as well as IFN-7 and IL-2, was inferred in the early report of Procopio and coworkers (1985) . Our studies using the RHPA have both provided unequivocal evidence of IL-4 secretion by CD16+ NK cells, and revealed a marked heterogeneity amongst NK cells in their ability to secrete IFN-y or IL-4. However, without the application of either a variant of the RHPA called the 'sequential' RHPA, to visualise the secretion of both these cytokines by the same cells (Neill et al., 1987) , or their dual labelling by immunofluorescence (Anderson et al., 1990) , it is not possible to say whether the 1% of CD16+ cells which were seen to secrete IL-4 also secreted IFN-y. The possibility (Lewis et al., 1988; Anderson et al., 1990 (Chong et al., 1989) . The medium transfer experiments conducted in the present study also indicate that factors secreted by tumour cells in culture, may be involved in the activation of NK cell secretory activity by the microenvironment of the tumour.
IL-4 has been shown to inhibit IFN-y production in mononuclear cells (Peleman et al., 1989) . Our finding that both IL-4 and IFN-y levels were elevated in human breast tumours suggests that, at least for a proportion of the tumour-associated NK cell population, this negative feedback loop may not be operative. The increased secretion of these two cytokines by NK cells within the tumour may have numerous implications for both tumour progression and the regulation of cell-mediated cytotoxicity against tumour cells. It is likely that they are two, amongst many cytokines which have been implicated as mediators of the intercellular communication which takes place within malignant tumours. Indeed, these often act back on the producer cell itself in an autocrine fashion (for review, see Lewis, 1991) . Both cytokines stimulate the secretory activity of human NK cells in vitro and can modulate the induction of LAK cell activity (Mule et al., 1987; Widmer et al., 1987; Giovarelli et al., 1988 al., 1988; Hart et al., 1989) .
It is also known to inhibit macrophage activation by IFN-y (Lehn et al., 1989) . The differential effects of IL-4 on NK cell activity and inhibition of macrophage cytotoxicity make it difficult to predict the overall effect of increased IL-4 levels for the tumour-bearing host. However, in transgenic mice producing high levels of IL-4, there is evidence for reduced tumour growth (Tepper et al., 1989) .
The role of IL-4 receptors which have been shown to be expressed on neoplastic epithelial cells and fibroblasts (Al Jabari et al., 1989 ) has yet to be established, but raises the possibility that IL-4 is able to modulate tumour cell function directly. In the case of IFN-y, Jabrane-Ferrat and coworkers (1990) have shown that this cytokine protects human breast cancer cells from NK and LAK cell lysis. However, such an effect might be specific to malignant breast cells, as this interferon is reported to increase in susceptibility of a neuroblastoma cell line to cell-mediate cytotoxicity (Handgretinger et al., 1989) . In addition, our own recent studies have indicated a role for IFN-y and IL-4 in regulating the growth of breast cancer cell lines in vitro (Pusztai et al., 1991) .
The cellular mechanism(s), by which tumour cells might play a part in stimulating the secretion of IL-4 and IFN-y by NK cells remain(s) to be identified. The possibility exists that the elevated level of cytokine released by tumour-associated NK cells reported here may have resulted, not so much from their exposure to activating factors produced within the tumour, but rather their release from local inhibitory influences. However, this seems unlikely since we have also demonstrated that medium conditioned by breast cancer cell lines stimulates, rather than inhibits, cytokine secretion by human NK cells in vitro. Cytokines may be secreted by neoplastic cells which directly modify the secretory activity of NK cells. Indeed, we have recently shown that one putative tumour cell product, namely basic form of fibroblast growth factor markedly enhances the secretion of IFN-y by human CD16+ NK cells in vitro . It is, therefore, possible that this and/or other cytokines secreted by the neoplastic cell population may play a part in the stimulation of NK cell secretory activity at the tumour site. They may also play a part in the mitogenic stimulation of lymphocytes by tumour cell lines recently reported by Packard (1990) .
Taken together, the studies outlined in this report demonstrate that soluble, tumour-specific signals augment the secretion of IFN-y and IL-4 by human CD16+ NK cells, and that the neoplastic cell population is one potential source of such stimulatory factors.
